Brokerages Anticipate AngioDynamics, Inc. (NASDAQ:ANGO) Will Announce Quarterly Sales of $67.61 Million

Equities research analysts forecast that AngioDynamics, Inc. (NASDAQ:ANGO) will announce $67.61 million in sales for the current quarter, Zacks Investment Research reports. Two analysts have issued estimates for AngioDynamics’ earnings, with the lowest sales estimate coming in at $67.30 million and the highest estimate coming in at $67.92 million. AngioDynamics posted sales of $85.34 million during the same quarter last year, which would indicate a negative year over year growth rate of 20.8%. The firm is expected to report its next earnings results on Thursday, September 26th.

On average, analysts expect that AngioDynamics will report full year sales of $282.72 million for the current fiscal year, with estimates ranging from $282.64 million to $282.80 million. For the next fiscal year, analysts anticipate that the firm will post sales of $302.05 million, with estimates ranging from $301.20 million to $302.90 million. Zacks’ sales calculations are an average based on a survey of sell-side analysts that that provide coverage for AngioDynamics.

AngioDynamics (NASDAQ:ANGO) last announced its earnings results on Wednesday, July 10th. The medical instruments supplier reported $0.25 EPS for the quarter, missing analysts’ consensus estimates of $0.26 by ($0.01). AngioDynamics had a net margin of 17.06% and a return on equity of 5.58%. The company had revenue of $96.30 million for the quarter, compared to analyst estimates of $92.34 million. During the same quarter last year, the company posted $0.20 EPS. AngioDynamics’s quarterly revenue was up 9.1% compared to the same quarter last year.



A number of research analysts have weighed in on the company. TheStreet lowered AngioDynamics from a “b” rating to a “c” rating in a research note on Monday, July 29th. BidaskClub lowered AngioDynamics from a “buy” rating to a “hold” rating in a research note on Tuesday, July 30th. Zacks Investment Research raised AngioDynamics from a “sell” rating to a “hold” rating and set a $20.00 price target on the stock in a research note on Tuesday, June 4th. Finally, ValuEngine raised AngioDynamics from a “hold” rating to a “buy” rating in a research note on Tuesday, July 2nd. Three analysts have rated the stock with a hold rating and one has given a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and an average price target of $21.50.

Shares of AngioDynamics stock traded up $0.09 during trading hours on Tuesday, reaching $18.84. 623 shares of the company’s stock were exchanged, compared to its average volume of 224,046. AngioDynamics has a 52-week low of $18.11 and a 52-week high of $25.48. The firm has a market capitalization of $712.36 million, a price-to-earnings ratio of 22.72 and a beta of 0.66. The company has a fifty day moving average of $20.47 and a 200-day moving average of $20.96. The company has a current ratio of 4.30, a quick ratio of 3.75 and a debt-to-equity ratio of 0.20.

In related news, Director Kevin J. Gould sold 13,650 shares of the stock in a transaction on Tuesday, July 16th. The stock was sold at an average price of $21.45, for a total value of $292,792.50. Following the transaction, the director now directly owns 61,774 shares of the company’s stock, valued at approximately $1,325,052.30. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Company insiders own 2.80% of the company’s stock.

Several institutional investors and hedge funds have recently modified their holdings of the stock. Nuveen Asset Management LLC bought a new stake in shares of AngioDynamics during the second quarter valued at approximately $4,865,000. Price T Rowe Associates Inc. MD raised its holdings in shares of AngioDynamics by 27.1% during the second quarter. Price T Rowe Associates Inc. MD now owns 607,751 shares of the medical instruments supplier’s stock valued at $11,967,000 after buying an additional 129,497 shares during the last quarter. Victory Capital Management Inc. raised its holdings in shares of AngioDynamics by 40.5% during the second quarter. Victory Capital Management Inc. now owns 3,773,543 shares of the medical instruments supplier’s stock valued at $74,301,000 after buying an additional 1,086,847 shares during the last quarter. UBS Asset Management Americas Inc. raised its holdings in shares of AngioDynamics by 3.5% during the second quarter. UBS Asset Management Americas Inc. now owns 21,784 shares of the medical instruments supplier’s stock valued at $429,000 after buying an additional 746 shares during the last quarter. Finally, Cubist Systematic Strategies LLC bought a new stake in shares of AngioDynamics during the second quarter valued at approximately $419,000. 98.37% of the stock is currently owned by institutional investors and hedge funds.

About AngioDynamics

AngioDynamics, Inc designs, manufactures, and sells various medical, surgical, and diagnostic devices for the treatment of peripheral vascular disease, vascular access, and for use in oncology and surgical settings in the United States and internationally. The company provides AngioVac venous drainage system that includes venous drainage cannula for the removal of fresh, soft thrombi, or emboli during extracorporeal bypass; and cardiopulmonary bypass circuit for use in procedures during extracorporeal circulatory support.

Featured Story: What are retained earnings?

Get a free copy of the Zacks research report on AngioDynamics (ANGO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for AngioDynamics (NASDAQ:ANGO)

Receive News & Ratings for AngioDynamics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AngioDynamics and related companies with MarketBeat.com's FREE daily email newsletter.